


CPA/1646
RECEIVED
JAN 17 2002
TECH CENTER 1600/2900

#22
Mg
1/31/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Douglas CLARY**
Title: ***Methods Of Evaluating Specific Cellular Functions Of Receptor Protein Tyrosine Kinases In A Ligand Independent Manner***
Appl. No.: **09/057,150**
Filing Date: **April 7, 1998**
CPA Filed: **January 14, 2002**
Examiner: **Nirmal Basi**
Art Unit: **1646**

CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL

Commissioner for Patents
BOX CPA
Washington, D.C. 20231

Sir:

This is a request under 37 C.F.R. § 1.53(d), Continued Prosecution Application (CPA), for a:

☒ Continuation ☐ Divisional

application of the above-identified prior nonprovisional application of:

Douglas CLARY

in which no payment of issue fee, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this CPA.

- ☐ Applicant claims small entity status under 37 CFR 1.27.
- ☐ Please enter the unentered amendment previously filed on __ in the prior application.
- ☒ Please enter the enclosed Preliminary Amendment.

Enclosed are:

- ☐ Small Entity statement.
- ☒ Information Disclosure Statement.
- ☒ Form PTO-1449 with copies of 9 listed reference(s).

☒ Application Data Sheet (37 CFR 1.76).☒ One Month Petition for Extension of Time.

The filing fee is calculated below:


	Claims as Amended		Previously Paid For		Extra Claims		Rate		Fee Totals
Basic Fee							\$740.00		\$740.00
Total Claims:	19	-	20	=	0	x	\$18.00	=	\$0.00
Independents:	3	-	3	=	0	x	\$84.00	=	\$0.00
If any Multiple Dependent Claim(s) present:						+	\$280.00	=	\$0.00
							SUBTOTAL:	=	\$740.00
One Month Petition for Extension of Time									\$110.00
<input type="checkbox"/>							Small Entity Fees Apply (subtract ½ of above):	=	
							TOTAL FILING FEE:	=	\$850.00

☐ Applicant requests suspension of action under 37 CFR 1.103(b) (fee under 37 CFR 1.17(i) enclosed).☒ A check in the amount of \$850.00 to cover the filing fee is enclosed.☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

By

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087Date January 14, 2002FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Douglas CLARY**


Title: *Methods Of Evaluating Specific Cellular Functions Of Receptor Protein Tyrosine Kinases In A Ligand Independent Manner*

Appl. No.: **09/057,150**

Filing Date: **April 7, 1998**

Examiner: **N. Basi**

Art Unit: **1646**



TECH CENTER 1600/2900

JAN 17 2002

RECEIVED

#24
Jg
1/31/02

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231
Sir:

Prior to examination of the present application, Applicants respectfully request that the following arguments be considered:

Applicant concurrently files herewith a Petition for Extension of Time under 37 C.F.R. § 1.136(a), with provision for the required fee, to extend the period for response for one month up to, and including, January 14, 2002. If additional fees are necessary to prevent abandonment of this application, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741.

REMARKS

Status of the Claims

Upon entry of this Amendment, claims 1, 6-8, 11, 16-18 and 20-29 will remain pending in the application, with claims 23-29 ready to be examined on the merits and claims 1, 6-8, 11, 16-18 and 20-22 withdrawn from consideration.